Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience

Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience

This study aimed to determine the real-world, long-term prognostic impacts, and adverse effects (AEs) of bevacizumab (BEV) in Asian patients with ovarian/tubal/peritoneal cancers. We retrospectively reviewed the medical records of consecutive patients with ovarian/tubal/peritoneal cancer on front-li...

Full description

Bibliographic Details
Main Authors: Pei-Ying Wu, Ya-Min Cheng, Meng-Ru Shen, Yi-Chun Chen, Yu-Fang Huang, Cheng-Yang Chou
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Oncology
Subjects:
ovarian cancer
fallopian cancer
peritoneal cancer
bevacizumab
progression
survival
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01095/full

Similar Items

Similar Items